CAJ | 학술논문

目的观察拉米夫定治疗乙肝失代偿期肝硬化患者抗病毒治疗的疗效。方法将符合标准30例乙肝失代偿期肝硬化患者随机分为治疗组和对照组，每组15例，两组均采用常规保肝基础治疗的同时，治疗组加用拉米夫定100mg/d口服，观察治疗6月，比较患者治疗前后临床表现、肝功、HBV-DNA、HBeAg阴转等改变情况。结果治疗组肝功能恢复情况、HBeAg转阴及HBV-DNA转阴均优于对照组(<0.05)。结论乙肝失代偿期肝硬化患者应用拉米夫定治疗可以有效提高临床疗效，值得临床、特别是在基层医院推广使用。
목적관찰랍미부정치료을간실대상기간경화환자항병독치료적료효。방법장부합표준30례을간실대상기간경화환자수궤분위치료조화대조조，매조15례，량조균채용상규보간기출치료적동시，치료조가용랍미부정100mg/d구복，관찰치료6월，비교환자치료전후림상표현、간공、HBV-DNA、HBeAg음전등개변정황。결과치료조간공능회복정황、HBeAg전음급HBV-DNA전음균우우대조조(<0.05)。결론을간실대상기간경화환자응용랍미부정치료가이유효제고림상료효，치득림상、특별시재기층의원추엄사용。
Objective To observe the antivira ef ect of the lamivudine treatment for de-compensated cir hosis patient due to hepatitis B.Methods 30 patients with hepatitis B decompensated Cir hosis were randomly divided into treatment group and controlGroup,15cases in each group.The patients in the control group were given routine liver treatment,while those in the treatment group were added lamivudine based on the treatment of the control group,received oral pul Mif given 100 mg/d,6 months,compared Clinical manifestations,liver function,the HBV-DNA and HBeAg negative change before and after Treatment.Results The Recovery of liver function,The HBeAg and HBV-DNA negative in treatment group was higher than that of control group,the dif erences were statistical significant( <0.05).Conclusion Lamivudine in the treatment of hepatitis B patients with decompensated cir hosis can ef ectively improve the clinical ef icacy,is worthy of clinical use,especial y in Basic hospital.